Navigation Links
Auxilium Pharmaceuticals to Present at the Morgan Stanley 2011 Healthcare Conference
Date:8/31/2011

MALVERN, Pa., Aug. 31, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Morgan Stanley 2011 Healthcare Conference during September 13-14, 2011 at the Grand Hyatt New York.  Mr. Armando Anido, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 8:35 am ET on Wednesday, September 14, 2011.  

(Logo  http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

To listen to the audio webcast of the presentation during or after the event, please visit: http://www.auxilium.com. The replays will be available for ninety days after the event.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists. Auxilium markets XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a testosterone gel, for the topical treatment of hypogonadism in the U.S. Pfizer Inc. has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia and Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan. Ferring International Center S.A. markets Testim in the EU and Paladin Labs Inc. markets Testim in Canada. Auxilium has two projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to present at the  Morgan Stanley 2011 Health Care Conference; and products in development for Peyronie's disease and Frozen Shoulder syndrome; and all other statements containing projections, statements of future performance or expectations, our beliefs or statements of plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Forward-looking statements can generally be identified by words such as "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and other words and terms of similar meaning in connection with any discussion of projections, future performance or expectations, beliefs, plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2010 and the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2011, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of Auxilium's home page on the Internet at http://www.Auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.

Contacts:
James E. Fickenscher/CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
jfickenscher@auxilium.com

William Q. Sargent Jr./ VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
wsargent@auxilium.com


'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
2. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
3. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
4. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
5. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
6. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
7. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
8. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
9. Anadys Pharmaceuticals to Report Second Quarter 2011 Financial Results
10. Optimer Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2011 Financial Results on August 3, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , ... May 24, 2016 , ... ... newly re-branded identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization ... imaging and image analysis. The re-branding components include a crisp, refreshed logo and ...
(Date:5/23/2016)... 23, 2016 - Leading CRO,s Use of ... - Frontage Implement a Single Platform to Manage End-to-end Operations Across ... the Bioanalytical lab Frontage Laboratories, a full-service contract research ... and China , has selected IDBS, ... addition to serving as the global electronic lab notebook (ELN), the ...
(Date:5/20/2016)... ... 2016 , ... Kablooe Design, a leading provider of product design and development ... of the business. “We have worked hard to build long-term relationships,” says President and ... and honor of serving their product design and development needs through the years.” , ...
(Date:5/19/2016)... NEW YORK , May 19, 2016 ... Biotech space will fully recover given the relentless pressures ... is for sure in the investors circle though - ... requires due-diligence. Ahead of today,s session, ActiveWallSt.com,s presents four ... PTLA ), Vitae Pharmaceuticals Inc. (NASDAQ: ...
Breaking Biology Technology:
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
(Date:3/9/2016)... NEW YORK , March 9, 2016 ... current and future states of the RNA Sequencing (RNA ... in segments such as instruments, tools and reagents, data ... Analyze various segments of the RNA-Sequencing market such ... RNA-Sequencing services Identify the main factors affecting each segment ...
(Date:3/9/2016)... Fla. , March 9, 2016  Crossmatch ... authentication and enrollment solutions, today announced the addition ... ® Altus multi-factor authentication platform. New ... InfoSec managers to step-up security where it,s needed ... Washington, DC . --> ...
Breaking Biology News(10 mins):